Actavis changes its name to Allergan
pharmafile | June 16, 2015 | News story | Medical Communications, Sales and Marketing | Actavis, Allergan, Botox, Valeant
Actavis has now officially changed its name to Allergan following the Ireland-based company’s recent acquisition of the botox maker.
This newly-merged Allergan has now begun a global rebranding campaign that will transition its facilities and operations to the new company name. However, it points out that the firm’s US and Canadian generics business will continue to operate under the Actavis tag due to its familiarity with customers.
“Today is an exciting day for Allergan and our 30,000 employees around the world who have helped us reach this special moment,” says the chief executive and president of Allergan, Brent Saunders.
“By adopting the Allergan name, we are ensuring that our corporate identity reflects the transformation of our company within the pharmaceutical industry and our position as a dynamic new breed of company – a leader in growth pharma.
“Allergan is home to world-renowned brands, the best-in-class global generics business, a premier pharmaceutical pipeline of medicines including brands, generics, biosimilars, OTC products and devices, as well as the fourth largest distributor in the US, which will retain the name Anda.”
Actavis bought Allergan in 2014’s biggest M&A deal which weighed in at $66 billion. The Dublin-based company fended off Valeant Pharmaceuticals to gain the firm in what was quite a takeover battle.
Last month Actavis said it expected revenues of up to $21 billion this year, and added that the combined entity creates one of the world’s largest drug makers in terms of sales, offering a range of stomach, skin and eye drugs.
But no rebranding would be complete without a new website and logo, both of which can be viewed here. The new icon in the logo – it says – “speaks to the strength of the company’s unique capabilities, the energy and passion of its people and its forward momentum.
“The circular shapes personify movement; purposeful paths of change and growth; growing spheres of influence and ideas; and achievement across brands and generics.”
Brett Wells
Related Content
FDA rejects Allergan’s Abicipar pegol for neovascular age-related macular degeneration over benefit/risk concerns
The FDA has moved to reject Allergan’s vascular endothelial growth factor (VEGF) factor A inhibitor, …
$63bn Allergan/AbbVie merger review could be delayed by coronavirus
The $63 billion merger of major pharma players AbbVie and Allergan could be facing hurdles …
Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine
New Phase 3 data has been released showing that both 50mg and 100mg doses of …
